Cargando…
Pharmacogenomics in practice: a review and implementation guide
Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study of interindividual variations in DNA sequence related to drug response, into routine clinical practice. In this article, we first briefly describe PGx and its role in improving treatment outcomes. We then propose a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233068/ https://www.ncbi.nlm.nih.gov/pubmed/37274118 http://dx.doi.org/10.3389/fphar.2023.1189976 |
_version_ | 1785052151761862656 |
---|---|
author | Kabbani, Danya Akika, Reem Wahid, Ahmed Daly, Ann K. Cascorbi, Ingolf Zgheib, Nathalie Khoueiry |
author_facet | Kabbani, Danya Akika, Reem Wahid, Ahmed Daly, Ann K. Cascorbi, Ingolf Zgheib, Nathalie Khoueiry |
author_sort | Kabbani, Danya |
collection | PubMed |
description | Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study of interindividual variations in DNA sequence related to drug response, into routine clinical practice. In this article, we first briefly describe PGx and its role in improving treatment outcomes. We then propose an approach to initiate clinical PGx in the hospital setting. One should first evaluate the available PGx evidence, review the most relevant drugs, and narrow down to the most actionable drug-gene pairs and related variant alleles. This is done based on data curated and evaluated by experts such as the pharmacogenomics knowledge implementation (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), as well as drug regulatory authorities such as the US Food and Drug Administration (FDA) and European Medicinal Agency (EMA). The next step is to differentiate reactive point of care from preemptive testing and decide on the genotyping strategy being a candidate or panel testing, each of which has its pros and cons, then work out the best way to interpret and report PGx test results with the option of integration into electronic health records and clinical decision support systems. After test authorization or testing requirements by the government or drug regulators, putting the plan into action involves several stakeholders, with the hospital leadership supporting the process and communicating with payers, the pharmacy and therapeutics committee leading the process in collaboration with the hospital laboratory and information technology department, and healthcare providers (HCPs) ordering the test, understanding the results, making the appropriate therapeutic decisions, and explaining them to the patient. We conclude by recommending some strategies to further advance the implementation of PGx in practice, such as the need to educate HCPs and patients, and to push for more tests’ reimbursement. We also guide the reader to available PGx resources and examples of PGx implementation programs and initiatives. |
format | Online Article Text |
id | pubmed-10233068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102330682023-06-02 Pharmacogenomics in practice: a review and implementation guide Kabbani, Danya Akika, Reem Wahid, Ahmed Daly, Ann K. Cascorbi, Ingolf Zgheib, Nathalie Khoueiry Front Pharmacol Pharmacology Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study of interindividual variations in DNA sequence related to drug response, into routine clinical practice. In this article, we first briefly describe PGx and its role in improving treatment outcomes. We then propose an approach to initiate clinical PGx in the hospital setting. One should first evaluate the available PGx evidence, review the most relevant drugs, and narrow down to the most actionable drug-gene pairs and related variant alleles. This is done based on data curated and evaluated by experts such as the pharmacogenomics knowledge implementation (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), as well as drug regulatory authorities such as the US Food and Drug Administration (FDA) and European Medicinal Agency (EMA). The next step is to differentiate reactive point of care from preemptive testing and decide on the genotyping strategy being a candidate or panel testing, each of which has its pros and cons, then work out the best way to interpret and report PGx test results with the option of integration into electronic health records and clinical decision support systems. After test authorization or testing requirements by the government or drug regulators, putting the plan into action involves several stakeholders, with the hospital leadership supporting the process and communicating with payers, the pharmacy and therapeutics committee leading the process in collaboration with the hospital laboratory and information technology department, and healthcare providers (HCPs) ordering the test, understanding the results, making the appropriate therapeutic decisions, and explaining them to the patient. We conclude by recommending some strategies to further advance the implementation of PGx in practice, such as the need to educate HCPs and patients, and to push for more tests’ reimbursement. We also guide the reader to available PGx resources and examples of PGx implementation programs and initiatives. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10233068/ /pubmed/37274118 http://dx.doi.org/10.3389/fphar.2023.1189976 Text en Copyright © 2023 Kabbani, Akika, Wahid, Daly, Cascorbi and Zgheib. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Kabbani, Danya Akika, Reem Wahid, Ahmed Daly, Ann K. Cascorbi, Ingolf Zgheib, Nathalie Khoueiry Pharmacogenomics in practice: a review and implementation guide |
title | Pharmacogenomics in practice: a review and implementation guide |
title_full | Pharmacogenomics in practice: a review and implementation guide |
title_fullStr | Pharmacogenomics in practice: a review and implementation guide |
title_full_unstemmed | Pharmacogenomics in practice: a review and implementation guide |
title_short | Pharmacogenomics in practice: a review and implementation guide |
title_sort | pharmacogenomics in practice: a review and implementation guide |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233068/ https://www.ncbi.nlm.nih.gov/pubmed/37274118 http://dx.doi.org/10.3389/fphar.2023.1189976 |
work_keys_str_mv | AT kabbanidanya pharmacogenomicsinpracticeareviewandimplementationguide AT akikareem pharmacogenomicsinpracticeareviewandimplementationguide AT wahidahmed pharmacogenomicsinpracticeareviewandimplementationguide AT dalyannk pharmacogenomicsinpracticeareviewandimplementationguide AT cascorbiingolf pharmacogenomicsinpracticeareviewandimplementationguide AT zgheibnathaliekhoueiry pharmacogenomicsinpracticeareviewandimplementationguide |